The company develops antibody therapeutics and low-molecular compound therapeutics that inhibit tumor-associated macrophages, which are known to enhance cancer cell metabolism. This approach provides cancer patients with targeted treatment options and a companion diagnostic method to personalize their therapy.
Funding
Funding not disclosed
Founders
Product
Problem
Current cancer treatments primarily target cancer cells, often overlooking the critical role of tumor-associated macrophages (TAMs) in promoting cancer cell metabolism and creating an environment conducive to tumor growth. This limited approach can lead to treatment resistance and incomplete eradication of the disease.
Solution
This startup develops antibody and small-molecule therapeutics designed to inhibit tumor-associated macrophages (TAMs), thereby disrupting the tumor microenvironment and hindering cancer cell metabolism. By targeting TAMs, the company aims to provide cancer patients with more effective and targeted treatment options. Furthermore, they are developing companion diagnostics to personalize therapy based on individual patient characteristics, potentially improving treatment outcomes.
Target Audience
The primary target audience includes cancer patients, oncologists, and pharmaceutical companies seeking novel and targeted cancer therapies.
Features
- Antibody therapeutics that selectively target and inhibit TAM function.
- Low-molecular compound therapeutics designed to modulate the tumor microenvironment.
- Companion diagnostic method to identify patients most likely to respond to TAM-targeted therapies.
- Focus on modulating the tumor microenvironment to overcome limitations of existing cancer treatments.